Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MapLight Therapeutics, Inc. (MPLT : NSDQ)

• Company Description    MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company's lead product candidate includes ML-007C-MA. MapLight Therapeutics Inc. is based in SAN FRANCISCO. Number of Employees: 133

• Price / Volume Information    Yesterday's Closing Price: $28.75 Daily Weekly Monthly 20 Day Moving Average: 272,609 shares Shares Outstanding: 42.62 (millions) Market Capitalization: $1,225.27 (millions) Beta: 52 Week High: $33.28 52 Week Low: $12.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.24% -6.06% 12 Week 65.04% 52.57% Year To Date 63.68% 53.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 800 Chesapeake Drive - Redwood City,CA 94063 USA ph: 617-984-6300 fax: - investors@maplightrx.com http://www.maplightrx.com

• General Corporate Information    Officers Christopher A. Kroeger - Chief Executive Officer Vishwas Setia - Chief Financial Officer Timothy Garnett - Director Nanna Luneborg - Director George Pavlov - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 56565P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 42.62 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,225.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 45.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - - 12/31/25 - - 09/30/25 - - Current Ratio 03/31/26 - 22.91 12/31/25 - 20.01 09/30/25 - 13.22 Quick Ratio 03/31/26 - 22.91 12/31/25 - 20.01 09/30/25 - 13.22 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 9.38 12/31/25 - 10.10 09/30/25 - -6.62 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©